Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
Portfolio Pulse from Benzinga Neuro
The global market for weight-loss drugs is projected to reach $150 billion by the early 2030s, driven by increased supply and demand for medications from Novo Nordisk and Eli Lilly. Despite limited insurance coverage, consumer demand remains high, with significant out-of-pocket spending. The market is expected to grow at an annual rate of 27%, potentially higher with expanded insurance coverage.
May 29, 2024 | 9:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The Tema Obesity & Cardiometabolic ETF is likely to benefit from the projected growth in the weight-loss drug market, driven by companies like Novo Nordisk and Eli Lilly.
The ETF, which focuses on obesity and cardiometabolic treatments, stands to gain from the projected market growth driven by major players like Novo Nordisk and Eli Lilly.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Eli Lilly's weight-loss drugs are a key factor in the projected $150 billion market by the early 2030s. Strong consumer demand and increased supply are driving growth.
Eli Lilly's weight-loss drugs are significantly contributing to the market's projected growth. The company's ability to ramp up supply to meet strong consumer demand positions it well for revenue growth.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Novo Nordisk's weight-loss drugs are contributing to a projected $150 billion market by the early 2030s. Despite high prices and limited insurance coverage, consumer demand is strong.
Novo Nordisk's weight-loss drugs, including Ozempic and Wegovy, are in high demand, contributing significantly to the projected market growth. Despite high prices and limited insurance coverage, consumer willingness to pay out-of-pocket indicates strong revenue potential.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100